. 2013 Nov 6;8(2):161–168. doi: 10.1016/j.molonc.2013.10.005

Table 1.

Comparison of the major phenotypes associated with Brca2‐deficient PDAC in three GEMMs. Each model employs distinct Brca2 alleles, in the context of different initiating lesions. Possible mechanisms underlying the variations in phenotype are discussed in the main text.

Study	Cohort	Associated phenotype
Skoulidis et al., 2010	Kras^G12D	15% tumour penetrance with long latency; 100% PDAC
	Kras^G12D, Brca2^Tr/Wt	Accelerated tumourigenesis with an increase in tumour penetrance at 30%; 100% PDAC
	Kras^G12D, Brca2^Tr/F11	Pancreatic insufficiency; some tumours develop but with long latency; 100% PDAC
	Kras^G12D, Tp53^R270H, Brca2^Wt/Wt	Highly penetrant tumour formation with a median survival of 168 days; 100% PDAC
	Kras^G12D, Tp53^R270H, Brca2^Tr/Wt	Accelerated tumourigenesis, median survival 143 days, in comparison to Brca2Wt; 100% PDAC
	Kras^G12D, Tp53^R270H, Brca2^Tr/F11	Further acceleration of tumourigenesis, median survival 84 days, all tumours showed regions of PDAC development with noted regions of Acinar histology in 18% of cases
Rowley et al., 2011	Kras^G12D	61% tumour penetrance with median survival 406 days
	Kras^G12D, Brca2^F11/Wt	66% tumour penetrance with median survival 366 days‐ similar to Brca2^Wt
	Kras^G12D, Brca2^F11/F11	Pancreatic insufficiency; 13% tumour penetrance with long latency
	Brca2^Wt/Wt	No tumour formation
	Brca2^F11/Wt	No tumour formation
	Brca2^F11/F11	No tumour formation
	Tp53^{F2‐10/F2‐10}, Brca2^Wt/Wt	Low tumour penetrance with acinar histology
	Tp53^{F2‐10/F2‐10}, Brca2^F11/Wt	Similar penetrance of tumour formation to Brca2Wt but with the associated histology of Brca2^F11/F11
	Tp53^{F2‐10/F2‐10}, Brca2^F11/F11	Increased tumour penetrance and acceleration of tumour formation in comparison to Brca2^Wt of Brca2^F11/Wt Mixed histology: PDAC 40%, Acinar 15%, high‐grade undifferentiated 35%, remainder mucinous tumours. Median survival 300 days.
Feldmann et al., 2011	Brca2^F11/F11	Pancreatic insufficiency; development of PDAC but with incomplete penetrance (∼15%) at 15 months. Median survival 454 days.
Feldmann et al., 2011	Tp53^R172H, Brca2^F11/F11	Pancreatic insufficiency; highly penetrant PDAC formation (100%) at 15 months. Median survival 375 days.